Immune checkpoint blockade: a common denominator approach to cancer therapy.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
复制标题
DOI:
10.1016/j.ccell.2015.03.001
复制
发表时间:
2015-04-13
期刊:
影响因子:
50.3
通讯作者:
Pardoll DM
中科院分区:
文献类型:
--
作者:
Topalian SL;Drake CG;Pardoll DM
The immune system recognizes and is poised to eliminate cancer, but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.
登录
查看更多内容
DOI:
10.1056/nejmoa1003466
发表时间:
2010-08-19
期刊:
The New England journal of medicine
影响因子:
--
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者:
Urba WJ
影响因子:
3.6
作者:
Dijkstra, JM;Somamoto, T;Fischer, U
通讯作者:
Fischer, U
影响因子:
64.5
作者:
FLEURY, S;LAMARRE, D;SEKALY, RP
通讯作者:
SEKALY, RP
影响因子:
30.5
作者:
Blackburn, Shawn D.;Shin, Haina;Haining, W. Nicholas;Zou, Tao;Workman, Creg J.;Polley, Antonio;Betts, Michael R.;Freeman, Gordon J.;Vignali, Dario A. A.;Wherry, E. John
通讯作者:
Wherry, E. John
影响因子:
3.7
作者:
Baitsch, Lukas;Legat, Amandine;Speiser, Daniel E.
通讯作者:
Speiser, Daniel E.